In conclusion, we have established a vital role for HCRP-1 in PCa and our clinical analyses point the prospect of HCRP-1 as a potential molecular therapeutic target for highly aggressive prostate cancer. This evidence concerns the gene VPS37A and Familial prostate cancer.